CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation–Positive Non–Small Cell Lung Cancer
Jang Ho Lee, Eun Young Kim, Cheol-Kyu Park, Shin Yup Lee, Min ki Lee, Seong-Hoon Yoon, Jeong Eun Lee, Sang Hoon Lee, Seung Joon Kim, Sung Yong Lee, Jun Hyeok Lim, Tae-Won Jang, Seung Hun Jang, Kye Young Lee, Seung Hyeun Lee, Sei Hoon Yang, Dong Won Park, Chan Kwon Park, Hye Seon Kang, Chang Dong Yeo, Chang-Min Choi, Jae Cheol Lee
Cancer Research and Treatment. 2023;55(1):112-122.   Published online 2022 July 19    DOI: https://doi.org/10.4143/crt.2022.381

Excel Download

Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291)
OncoTargets and Therapy. 2017;Volume 10:1757-1766   Crossref logo
Link1 Link2

P8‐62: A phase II trial of osimertinib for elderly patients with epidermal growth factor receptor T790M‐positive non‐small cell lung cancer that progressed during previous treatment
Respirology. 2021;26(S3):311-312   Crossref logo
Link1 Link2 Link3

Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience
Therapeutic Advances in Respiratory Disease. 2016;10(6):549-565   Crossref logo
Link1 Link2 Link3

376P The impact of T790M mutation status for later-line osimertinib in non-small cell lung cancer patients with progression on frontline epidermal growth factor receptor tyrosine kinase inhibitor
Annals of Oncology. 2022;33:S1588   Crossref logo
Link1 Link2

Correction: Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in the USA
PLOS ONE. 2019;14(2):e0212831   Crossref logo
Link1

Real-world use of osimertinib for epidermal growth factor receptor T790M-positive non-small cell lung cancer in Japan
Japanese Journal of Clinical Oncology. 2020;50(8):909-919   Crossref logo
Link1 Link2

Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy
Therapeutic Advances in Medical Oncology. 2017;9(6):387-404   Crossref logo
Link1 Link2 Link3

363P A multicentre, real-world observational study of efficacy and safety of first-line osimertinib treatment in patients with epidermal growth factor receptor (EGFR) activating mutation-positive advanced non-small cell lung cancer (Reiwa study)
Annals of Oncology. 2022;33:S1583-S1584   Crossref logo
Link1 Link2

Real-World Data on Osimertinib in Chinese Patients with Pretreated, EGFR T790M Mutation Positive, Advanced Non-Small Cell Lung Cancer: A Retrospective Study
Cancer Management and Research. 2021;Volume 13:2033-2039   Crossref logo
Link1 Link2

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: Focus on epidermal growth factor receptor mutation testing and mutation-positive patients
Cancer Treatment Reviews. 2013;39(8):839-850   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.